Tirzepatide subcutaneous injection for type 2 diabetes

24th March 2024 by Dr Louise Hudman

Tirzepatide subcutaneous injection for type 2 diabetes

NICE released guidance on the use of tirzepatide for diabetes in October 2023.

What is tirzepatide?

Tirzepatide is an agonist at both the GLP-1 receptor (glucagon-like peptide 1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). Stimulation of these receptors causes an increase in the release of GLP-1 and GIP and these in turn cause an increased release of insulin, a reduced glucagon release and delayed gastric emptying.

It both improves diabetes control and increases weight loss.

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


Related content

"NASGP is very helpful to allow a safe and supportive way to work as a GP locum. NASGP Locum Chambers, particularly, is very useful. "

Dr Nabeel Virani, GP, Buckinghamshire

See the full list of features within our NASGP membership plans